Scandion has submitted a patent application regarding a novel mechanism of action for its lead compound SCO-101

Scandion Oncology has discovered a novel mechanism of action for its lead compound SCO-101. This mechanism of action is believed to be involved in re-sensitization of anti-cancer drug resistant cancer cells. Through its patent office, Høiberg, this invention was filed to EPO on September 6th, 2018.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union